What is the current stock price of Insight Molecular Diagnostics Inc. (IMDX)?

As of the latest market data, Insight Molecular Diagnostics Inc. (IMDX) is trading at $3.17. The stock has seen a loss of -0.31% today.

Does Insight Molecular Diagnostics Inc. (IMDX) pay a dividend?

Based on current data, Insight Molecular Diagnostics Inc. does not have a confirmed active dividend policy.

What is the market cap of Insight Molecular Diagnostics Inc.?

The current market capitalization of Insight Molecular Diagnostics Inc. (IMDX) is approximately unavailable.

IMDX

Insight Molecular Diagnostics Inc.·Healthcare

3.17

0.314%(−0.01)

Market Closed

3.83

20.820%(+0.66)

After Hours

Last Updated: — ET

52W L: $2.3352W H: $8.51

IMDX NEWS

seekingalpha.com

Mar 26

Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 26

IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:

globenewswire.com

Mar 20

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference

NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on Thursday, March 26, 2026.

globenewswire.com

Mar 13

Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score

NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today highlighted the publication of a new peer-reviewed study demonstrating the potential superiority of the company's flagship GraftAssureTM assay technology.

defenseworld.net

Mar 9

Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review

Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) are both manufacturing companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations. Profitability This table compares Anbio Biotechnology and Oncocyte's net

defenseworld.net

Mar 9

Head-To-Head Contrast: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN)

Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) are both manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership. Analyst Recommendations This is a breakdown of current ratings

Company Profile

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2015-12-30

Beta

1.53

Websiteimdxinc.com↗